Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Nov 18;9(11):e003683. doi: 10.1136/jitc-2021-003683

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Race of eligible patients for immunotherapies and tumor mutation burden (TMB) cutoffs. (A) Proportions of patients with TMB-high or TMB-low cancers by race across The Cancer Genome Atlas (TCGA) and Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) cohorts. In the TCGA cohort, blacks (OR 0.72; 95% CI 0.55 to 0.93, p=0.01) and Asian (OR 0.54; 95% CI 0.39 to 0.76, p<0.001) patients were less likely to have cancers with high TMB. Similarly, in the MSK-IMPACT cohort, blacks (OR, 0.61; 95% CI 0.52 to 0.72, p<0.001) and Asian (OR, 0.52; 95% CI 0.44 to 0.62, p<0.001) patients were less likely to have cancers with high TMB. (B) Percent increase in patients across different race eligible for immunotherapy based on different TMB cutoffs.